Potentiation of anti-CD38-Immunotoxin cytotoxicity
The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.
1. A method of treating an individual having acute myeloid leukemia, acute promyelocytic leukemia, lymphoma or myeloma, comprising the steps of:
a) administering to said individual a pharmacologically effective dose of a retinoid which up-regulates the expression of CD38 antigen, followed by
b) administering to the same individual a pharmacologically effective dose of an immunotoxin directed to CD38,
wherein said retinoid is administered in a dose of from about 0.1 mg/kg to about 2 mg/kg.
2. The method of claim 1 , wherein said retinoid is a material selected from the group consisting of all-trans-retinoic acid (RA); 9-cis retinoic acid (9-cis RA); (E) 4[2(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); and, (E)-4-[2-(5,6,7,8,-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-propenyl]benzoic acid (3-met TTNPB).
3. The method of claim 1 , wherein said immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule.
4. The method of claim 3 , wherein said toxin is gelonin.
5. The method of claim 1 , wherein said acute promyelocytic leukemia is adriamycin resistant.
6. A method of treating an individual having acute myeloid leukemia, acute promyelocytic leukemia, lymphoma or myeloma, comprising the steps of:
a) administering to said individual a pharmacologically effective dose of a retinoid which up-regulates the expression of CD38 antigen, followed by
b) administering to the same individual a pharmacologically effective dose of an immunotoxin directed to CD38,
wherein said immunotoxin is administered in a dose of from about 0.05 mg/kg to about 2 mg/kg.
7. The method of claim 6 , wherein said retinoid is selected from the group consisting of all-trans-retinoic acid (RA); 9-cis retinoic acid (9-cis RA); (E) 4[2(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); and, (E)-4-[2-(5,6,7,8,-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1- propenyl]benzoic acid (3-met TTNPB).
8. The method of claim 6 , wherein said immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule.
9. The method of claim 8 , wherein said toxin is gelonin.
10. The method of claim 6 , wherein said acute promyelocytic leukemia is adriamycin resistant.